D-Wave Expands Quantum Computing Education in Italy Through National Seminar Series COMO, Italy – [Date], 2025 – D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or the “Company”), a global leader in quantum computing systems, software, and services, and the world’s first…
MindWalk Holdings Appoints R. Scott Areglado as Chief Financial Officer to Advance Financial Strategy and Support Global Growth MINNEAPOLIS, MN – October 23, 2025 – MindWalk Holdings Corp.™ (“MindWalk,” “the Company,” “we,” or “us”) (Nasdaq: HYFT), a bio-native artificial intelligence…
Stevanato Group S.p.A. to Announce Third Quarter 2025 Financial Results on November 6, 2025 Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group” or “the Company”), a leading global provider of drug containment, drug delivery, and diagnostic solutions serving the pharmaceutical, biotechnology,…
Ferrer Completes Patient Enrollment for the PROSPER Phase II Clinical Trial in Progressive Supranuclear Palsy Ahead of Schedule Barcelona, Spain — [October 2025] — Ferrer, the international pharmaceutical company headquartered in Spain, today announced the successful completion of patient recruitment…
Thermo Fisher Scientific Reports Strong Third Quarter 2025 Results, Advances Innovation and Strategic Growth WALTHAM, Mass., October 22, 2025 — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced its financial results for the third…
ProImmune Expands Global Headquarters to Drive Next-Generation Immunology and Life Science Innovation ProImmune Ltd, a global leader in life science reagents and immunology services, has officially opened its new global headquarters at Oasis Park in Oxford. The move marks a…
Global Study Highlights Survival Benefit of Mogamulizumab in Advanced Cutaneous T-Cell Lymphoma Birmingham, UK, and Tokyo, Japan – Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company,…
PureTech Health Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis Findings Highlight Potential for Deupirfenidone to Address a Critical Unmet Need in an Underserved Patient Population Boston, Mass. —…
GondolaBio’s PORT-77 Receives FDA Orphan Drug and Fast Track Designations for the Treatment of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) CAMBRIDGE, Mass., [Month] [Day], 2025 — GondolaBio, a clinical-stage biopharmaceutical company pioneering novel therapies for patients living with serious…
Iambic Therapeutics and Jazz Pharmaceuticals Announce Research Collaboration to Evaluate IAM1363 and Zanidatamab Combination in HER2-Positive Breast Cancer SAN DIEGO, Calif., October 22, 2025 – Iambic Therapeutics, a clinical-stage life science and technology company pioneering the use of artificial intelligence…